Xencor, Inc. Common Stock XNCR
i
Market dataready · fetched 2026-11-08T10:15:57.109Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:19:12.023851177Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-08T10:15:56.157068+00:00
Xencor, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 30.16 | 131.3% | 18.8% | |||
| 25Δ | 31.30 | 129.1% | 16.7% | |||
| 30Δ | 32.44 | 126.9% | 14.6% | |||
| 35Δ | 40.32 | 126.9% | 17.4% | 33.58 | 124.7% | 12.5% |
| 40Δ | 39.08 | 120.6% | 14.6% | 34.72 | 122.4% | 10.4% |
| 45Δ | 38.00 | 115.1% | 12.4% | 35.78 | 121.6% | 9.0% |
| 50Δ | 36.92 | 109.5% | 10.1% | 36.82 | 121.2% | 7.8% |
| 55Δ | 35.85 | 103.9% | 7.9% | 37.86 | 120.8% | 6.7% |
| 60Δ | 34.79 | 99.9% | 5.9% | 38.90 | 120.5% | 5.6% |
| 65Δ | 33.80 | 101.8% | 5.1% | 39.95 | 120.1% | 4.4% |
| 70Δ | 32.81 | 103.6% | 4.3% | 41.33 | 119.4% | 3.6% |
| 75Δ | 31.82 | 105.5% | 3.4% | 42.73 | 118.7% | 2.9% |
| 80Δ | 30.83 | 107.3% | 2.6% | 44.13 | 118.0% | 2.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.16
- IV
- 131.3%
- B/E move
- 18.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.30
- IV
- 129.1%
- B/E move
- 16.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 32.44
- IV
- 126.9%
- B/E move
- 14.6%
35Δ
- Pseudo strike
- 40.32
- IV
- 126.9%
- B/E move
- 17.4%
- Pseudo strike
- 33.58
- IV
- 124.7%
- B/E move
- 12.5%
40Δ
- Pseudo strike
- 39.08
- IV
- 120.6%
- B/E move
- 14.6%
- Pseudo strike
- 34.72
- IV
- 122.4%
- B/E move
- 10.4%
45Δ
- Pseudo strike
- 38.00
- IV
- 115.1%
- B/E move
- 12.4%
- Pseudo strike
- 35.78
- IV
- 121.6%
- B/E move
- 9.0%
50Δ
- Pseudo strike
- 36.92
- IV
- 109.5%
- B/E move
- 10.1%
- Pseudo strike
- 36.82
- IV
- 121.2%
- B/E move
- 7.8%
55Δ
- Pseudo strike
- 35.85
- IV
- 103.9%
- B/E move
- 7.9%
- Pseudo strike
- 37.86
- IV
- 120.8%
- B/E move
- 6.7%
60Δ
- Pseudo strike
- 34.79
- IV
- 99.9%
- B/E move
- 5.9%
- Pseudo strike
- 38.90
- IV
- 120.5%
- B/E move
- 5.6%
65Δ
- Pseudo strike
- 33.80
- IV
- 101.8%
- B/E move
- 5.1%
- Pseudo strike
- 39.95
- IV
- 120.1%
- B/E move
- 4.4%
70Δ
- Pseudo strike
- 32.81
- IV
- 103.6%
- B/E move
- 4.3%
- Pseudo strike
- 41.33
- IV
- 119.4%
- B/E move
- 3.6%
75Δ
- Pseudo strike
- 31.82
- IV
- 105.5%
- B/E move
- 3.4%
- Pseudo strike
- 42.73
- IV
- 118.7%
- B/E move
- 2.9%
80Δ
- Pseudo strike
- 30.83
- IV
- 107.3%
- B/E move
- 2.6%
- Pseudo strike
- 44.13
- IV
- 118.0%
- B/E move
- 2.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 113.18% | |
| 106.90% | |
| 104.50% | |
| 100.11% | |
| 103.01% | |
| 84.48% | |
| 87.11% | |
| 80.20% | |
| 82.27% | |
| 86.70% |
Biotechnology
ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is…
More →ZLAB
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is…
More →ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers.…
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Description unavailable
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →